Forum Institutional

6 essential steps to expanding health product manufacturing in Africa

Strengthening global health security means developing a sustainable, local manufacturing industry on the African continent.

Strengthening global health security means developing a sustainable, local manufacturing industry on the African continent. Image: Photo by Mika Baumeister on Unsplash

Dr. Nanthalile Mugala
Chief of the Africa Region, PATH
Johnpaul Omollo
Senior Policy and Advocacy Officer, PATH
Share:
Our Impact
What's the World Economic Forum doing to accelerate action on Forum Institutional?
The Big Picture
Explore and monitor how Health and Healthcare is affecting economies, industries and global issues
A hand holding a looking glass by a lake
Crowdsource Innovation
Get involved with our crowdsourced digital platform to deliver impact at scale
Stay up to date:

Davos Agenda

This article is part of: World Economic Forum Annual Meeting

Listen to the article

  • Africa has been largely reliant on other regions for medical supplies.
  • Stronger local production would mean more equitable access to life-saving health products.
  • Strengthening global health security means developing a sustainable, local manufacturing industry on the African continent.
  • Here are six key steps to take.

From the onset of the COVID-19 pandemic, Africa has remained among the last in line to access necessary medical supplies and tools — from personal protective equipment and diagnostics to treatments and vaccines.

Limited local manufacturing means that many countries were, and continue to be, reliant on imports. These challenges are not new — the pandemic merely highlighted the continent’s long-standing, inequitable access to lifesaving medical products. Vaccination rates in Africa are still far too low.

As a result, concerted efforts are underway to strengthen Africa’s capacity to develop and produce health products that meet its needs. Several countries already have capabilities in vaccine and drug manufacturing and fill and finish capacity — the steps that follow production, such as filling syringes, labelling, packaging and quality inspection. But there remains a significant gap to close.

Africa, which accounts for almost 17% of the world’s population, represents only 3% of global drug production. Most countries in sub-Saharan Africa import 70 to 90% of their consumed pharmaceuticals, according to McKinsey, a stark contrast to comparable populations in China and India, which import 5% and 20% respectively.

Davos 2023 ; Most sub-Saharan African countries are at the earliest stages of pharmaceutical-industry development.
The stages of development for the pharmaceutical industry. Image: McKinsey

How can Africa progress in manufacturing its own medical supplies

To strengthen global health security, we must support an agenda to develop a sustainable, local manufacturing industry on the African continent. This will increase access to life-saving health products and reduce reliance on other regions, especially when pandemics and other health crises strike.

These six steps will be critical to this process:

1. Private sector engagement and cross-sectoral collaboration

Increasing the African continent’s supply of key health products is a critical and under-resourced component of health system resilience. But we know that if commercial viability is the only deciding factor, companies will often opt out.

We need private-sector engagement and cross-sectoral collaboration to incentivize investment in these necessary public goods. Real advancement requires strong partnerships between governments, civil society, international organizations, multilateral organizations and the private sector.

By working together, we can better understand industry needs, from infrastructure and staffing to business plans and profit margins. Civil society and non-governmental organizations can help advocate for support from governments and multilateral organizations. At the same time, governments must create favourable policies to ensure businesses are willing and able to set affordable prices for equitable access.

2. Strong coordination across the manufacturing ecosystem

As the COVID-19 pandemic has shown us, one country or entity cannot create a robust system on its own. Singular, siloed efforts are unlikely to sustainably reach the necessary scale. It requires a coordinated manufacturing ecosystem.

The African Union and the Africa CDC’s Partnerships for African Vaccine Manufacturing Framework for Action offer a blueprint for how to accelerate local manufacturing in a coordinated way. This model could be replicated for diagnostics and therapeutics.

This must begin with an understanding of the existing capacity to then map a way forward for developing different types of products, which involve different levels of complexity to produce. For instance, in places without drug substance or product manufacturing capacity, it might be more efficient to begin developing fill and finish capacities, with a goal of building up over time to drug substance manufacturing.

3. Sustainable financing underpinned by government involvement

In the past few years, there has been considerable investment in manufacturing in Africa. Too often, however, these are one-time investments that don’t consider the full lifecycle of a product or the larger manufacturing ecosystem.

An effective, sustainable, manufacturing ecosystem requires long-term domestic and foreign financing from public sources, bilateral and multilateral funders and the private sector. This kind of flexible funding environment encourages innovation and enables long-term planning.

Investors should ensure that their investments are complementary to and supportive of, instead of competing with, existing efforts. This is why PATH’s Diagnostics team created a local diagnostics company dashboard that showcases more than 150 diagnostic developers, manufacturers and distributors in Africa, Asia and Latin America.

In addition to serving as an advocacy tool, the dashboard highlights investment opportunities. More than 70 companies in Africa, for example, are either headquartered in the region or have manufacturing capacity there. Yet, only 33 companies have reported having standard quality assurance certifications. Investing in quality assurance would be particularly valuable to enable more local manufacturers to meet the global quality standards for centralized procurement and broader market reach.

Finally, national governments have a special role to play. Governments should invest in research and development, good manufacturing compliance and clinical trials to incentivize the private sector. They can also offer subsidies, allocate land for factories and provide tax breaks to catalyze and strengthen local efforts.

Discover

How is the World Economic Forum ensuring sustainable global markets?

4. Streamlined regulatory environment

A streamlined regulatory system encourages domestic product development and ensures quality, safety and efficacy. To date, many African countries have weak, misaligned policies for the regulation of medical products, meaning it can often take years for a single product to be approved for use.

The newly established African Medicines Agency (AMA) is a continent-wide platform for strengthening and harmonizing continental and regional regulatory authorities. By pooling expertize and capacities and coordinating across countries and regions, the AMA will ensure more high-quality local products reach the people who need them.

Currently, 23 African countries have ratified the treaty. We encourage the remaining 32 (out of 55) member countries to fully ratify the AMA.

Loading...

5. Use technology co-creation to go beyond tech transfer

If the continent makes a concerted effort to scale its manufacturing ecosystem, it has the potential to create global goods that are fit for the African context. But to do so, African stakeholders must adapt preexisting technologies to serve the needs of their countries and communities more effectively.

Technology co-creation is the collaborative development of new products and services backed by experts and stakeholders (such as customers and suppliers). This differs from technology transfer — sharing technology with insufficient detail and only under limited terms — which leaves national manufacturers still dependent on foreign companies.

Co-creation ensures the needs and priorities of the target population are incorporated from the beginning. It also opens doors to a more sustainable and equitable process that is mutually beneficial for African countries and international partners alike.

6. Aggregating demand for local products

Even as more medical products are manufactured and approved in Africa, many local manufacturers will struggle to offer prices that are affordable for low- and middle-income countries, while also adequate enough to cover costs and remain in business.

To reach this balance, national governments and international and multilateral agencies must show meaningful leadership by purchasing African-made products. This requires policy and legislative reforms at the country level, especially for countries that have restrictive local procurement policies.

As outlined in the New Public Health Order for Africa, intentionally aggregating and coordinating demand for products will help make African manufacturing sustainable and viable.

Have you read?
  • How to follow Davos 2023
Don't miss any update on this topic

Create a free account and access your personalized content collection with our latest publications and analyses.

Sign up for free

License and Republishing

World Economic Forum articles may be republished in accordance with the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International Public License, and in accordance with our Terms of Use.

The views expressed in this article are those of the author alone and not the World Economic Forum.

Related topics:
Forum InstitutionalHealth and Healthcare Systems
Share:
World Economic Forum logo
Global Agenda

The Agenda Weekly

A weekly update of the most important issues driving the global agenda

Subscribe today

You can unsubscribe at any time using the link in our emails. For more details, review our privacy policy.

What to expect at the Special Meeting on Global Cooperation, Growth and Energy for Development

Spencer Feingold and Gayle Markovitz

April 19, 2024

About Us

Events

Media

Partners & Members

  • Join Us

Language Editions

Privacy Policy & Terms of Service

© 2024 World Economic Forum